Clinical Trials Directory

Trials / Unknown

UnknownNCT02407210

Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
304 (estimated)
Sponsor
Jiangsu HengRui Medicine Co., Ltd. · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

To investigate the efficacy and safety of azilsartan compared to olmesartan medoxomil in patients with grade I or II essential hypertension

Conditions

Interventions

TypeNameDescription
DRUGazilsartan
DRUGOlmesartan medoxomil

Timeline

Start date
2015-01-01
Primary completion
2015-10-01
First posted
2015-04-02
Last updated
2015-04-02

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02407210. Inclusion in this directory is not an endorsement.

Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential (NCT02407210) · Clinical Trials Directory